drugset / Trial / NCT02640976
Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program
Non-randomizedParallel-groupOpen-labelScreening
Summary
The aim of this study is to assess the role of AMH in prediction of poor ovarian response as well as the relation between ESR2 (+1730G\>A) (rs4986938), FSHR p.Thr307Ala (c.919A\>G, rs6165) and FSHR p.Asn680Ser (c.2039A\>G, rs6166) SNPs and the poor response in Egyptian women undergoing IVF procedure. Discovering the genetic variants associated with ovarian response is an important step towards individualized pharmacogenetic protocols of ovarian stimulation.
Timeline
- Start
- 2013-06
- Primary completion
- 2015-06
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Merional | Protein / enzyme biologic | 225 iu | Intramuscular |
| Comparator | Merional | Protein / enzyme biologic | 300 iu | Intramuscular |
| Comparator | Cetrorelix | Other / unclassified | 0.25 mg | Subcutaneous |
| Comparator | human chorionic gonadotropin | Protein / enzyme biologic | 10000 iu | Intramuscular |